

# Cost-effectiveness of a model consultation to support self-management in patients with osteoarthritis

Oppong, Raymond; Jowett, Sue

DOI:

[10.1093/rheumatology/key037](https://doi.org/10.1093/rheumatology/key037)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Oppong, R & Jowett, S 2018, 'Cost-effectiveness of a model consultation to support self-management in patients with osteoarthritis', *Rheumatology*. <https://doi.org/10.1093/rheumatology/key037>

[Link to publication on Research at Birmingham portal](#)

## **Publisher Rights Statement:**

This is a pre-copyedited, author-produced version of an article accepted for publication in *Rheumatology* following peer review. The version of record Raymond Oppong, Sue Jowett, Martyn Lewis, Kris Clarkson, Zoe Paskins, Peter Croft, John J Edwards, Emma Healey, Kelvin P Jordan, Andrew Morden, Bie Nio Ong, Mark Porcheret, Andrew Finney, Elaine Hay, Krysia Dziedzic; Cost-effectiveness of a model consultation to support self-management in patients with osteoarthritis, *Rheumatology* is available online at: <https://doi.org/10.1093/rheumatology/key037>

## **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

**Cost-effectiveness of a model consultation to support self-management in patients with osteoarthritis**

|   |  |
|---|--|
| Journal:  | <i>Rheumatology</i>  |
| Manuscript ID   | RHE-17-1589.R2   |
| Manuscript Type:  | Original Article (includes systematic reviews)   |
| Date Submitted by the Author:   | 23-Jan-2018  |
| Complete List of Authors:   | <p>Oppong, Raymond; University of Birmingham, Health Economics<br/>         Jowett, Sue; University of Birmingham, Health Economics Unit<br/>         Lewis, Martyn; Senior Lecturer in Statistics &amp; Health Economics, Primary Care Sciences Research Centre;<br/>         Clarkson, Kris; Keele University, Research Institute for Primary Care and Health Sciences<br/>         Paskins, Zoe; Keele University, Arthritis Research UK Primary Care Centre<br/>         Croft, Peter; Keele University, Arthritis Research UK Primary Care Centre<br/>         Edwards, John; Keele University, Arthritis Research UK Primary Care Centre<br/>         Healey, Emma; Keele University, Research Institute for Primary Care &amp; Health Sciences<br/>         Jordan, Kelvin; Keele University, Arthritis Research UK Primary Care Centre;<br/>         Morden, Andrew; Keele University, Research Institute for Primary Care and Health Sciences, Arthritis Research UK Primary Care Centre<br/>         Ong, Bie Nio; Keele University, Primary Care Sciences Research Centre;<br/>         Porcheret, Mark; Keele University, Research Institute for Primary Care &amp; Health Sciences<br/>         Finney, Andrew; Keele University, Arthritis Research UK Primary Care Centre; Keele University, School of Nursing and Midwifery<br/>         Hay, Elaine; ARC National Primary Care Centre, Primary Care Sciences<br/>         Dziedzic, Krysia; Keele University, Institute for Primary Care and Health Sciences,</p> |
| Keywords<br>Please select a minimum FIVE keywords from the list provided. These keywords will be used to select reviewers for this manuscript. The keywords in the main text of your paper do not need to match these words.: | Health economics < HEALTH SERVICES AND PRACTICE, Osteoarthritis < RHEUMATIC DISEASES, Primary care rheumatology < HEALTH SERVICES AND PRACTICE, Outcome measures < HEALTH SERVICES AND PRACTICE, Quality of life < PSYCHOLOGY AND SOCIAL PHENOMENA   |
|   |  |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

SCHOLARONE™  
Manuscripts

For Peer Review

1  
2  
3 **Cost-effectiveness of a model consultation to support self-management in**  
4  
5 **patients with osteoarthritis**  
6  
7  
8  
9

10  
11 **Raymond Oppong<sup>1,2</sup> Sue Jowett<sup>1,2\*</sup>, Martyn Lewis<sup>1,4</sup>, Kris Clarkson<sup>4</sup>, Zoe Paskins<sup>1,3</sup>,**  
12 **Peter Croft<sup>1</sup>, John J Edwards<sup>1</sup>, Emma Healey<sup>1</sup>, Kelvin P Jordan<sup>1,4</sup>, Andrew Morden<sup>1</sup>,**  
13 **Bie Nio Ong<sup>1</sup>, Mark Porcheret<sup>1</sup>, Andrew Finney<sup>1</sup>, Elaine Hay<sup>1</sup>, Krysia Dziedzic<sup>1</sup>**  
14  
15  
16  
17

18  
19 <sup>1</sup> Research Institute for Primary Care and Health Sciences, Arthritis Research UK Primary  
20 Care Centre, Keele University, Staffordshire, ST5 5BG  
21  
22

23  
24 <sup>2</sup> Health Economics Unit, University of Birmingham, Birmingham, B15 2TT  
25

26  
27 <sup>3</sup> Haywood Academic Rheumatology Centre, Staffordshire and Stoke-on-Trent Partnersip  
28 Trust, Stoke-on-Trent ST6 7AG  
29  
30

31  
32 <sup>4</sup> Keele Clinical Trials Unit, David Weatherall Building, Keele University, Staffordshire, ST5  
33 5BG  
34  
35

36  
37 \*Address for correspondence  
38

39  
40 Sue Jowett  
41

42  
43 Health Economics Unit  
44

45  
46 Public Health Building  
47

48  
49 University of Birmingham  
50

51  
52 B15 2TT  
53

54  
55 Email: [s.jowett@bham.ac.uk](mailto:s.jowett@bham.ac.uk)  
56  
57  
58  
59  
60

1  
2  
3 **Running title:** Cost-effectiveness of a model consultation for osteoarthritis  
4  
5  
6  
7

8  
9 **ABSTRACT**

10  
11 **Objectives:** The aim of this study was to estimate the cost-effectiveness of a model OA  
12  
13 consultation for osteoarthritis to support self-management compared with usual care.  
14  
15

16  
17 **Methods:** An incremental cost-utility analysis using patient responses to the 3-level EQ-5D  
18  
19 questionnaire was undertaken from a UK National Health Service perspective alongside a  
20  
21 two-arm cluster-randomised controlled trial. Uncertainty was explored through the use of  
22  
23 cost-effectiveness acceptability curves.  
24  
25

26  
27 **Results:** Differences in health outcomes between the model OA consultation and usual care  
28  
29 arms were not statistically significant. On average, visits to the orthopaedic surgeon were  
30  
31 lower in the model OA consultation arm -0.28 (95% CI: -0.55, -0.06). The cost-utility  
32  
33 analysis indicated that the model OA consultation was associated with a non-significant  
34  
35 incremental cost of £-13.11 (95% CI: -81.09, 54.85) and an incremental QALY of -0.003  
36  
37 (95% CI: -0.03, 0.02), with a 44% chance of being cost-effective at a threshold of £20,000  
38  
39 per QALY gained. The percentage of participants who took time off and the associated  
40  
41 productivity cost was lower in the model OA consultation arm.  
42  
43

44  
45 **Conclusion:** Implementing NICE guidelines using a model OA consultation in primary care  
46  
47 does not appear to lead to increased costs, but health outcomes remain very similar to usual  
48  
49 care. Even though the intervention seems to reduce the demand for orthopaedic surgery,  
50  
51 overall it is unlikely to be cost-effective.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Funding:** This paper presents independent research funded by the National Institute for  
4 Health Research (NIHR) Programme Grant (RP-PG-0407-10386) and the Arthritis Research  
5 UK Centre in Primary Care grant (Grant Number 18139). The views expressed in this paper  
6 are those of the authors and not necessarily those of the NHS, the NIHR or the Department of  
7 Health.  
8  
9  
10  
11  
12

13  
14 **Keywords:** Primary care, cost-effectiveness, NICE osteoarthritis guidelines, ICECAP, EQ-  
15 5D, implementation.  
16

### 17 18 19 **Key messages**

- 20  
21  
22 ~~• A model OA consultation offers a practical approach that supports self-management~~  
23 ~~of OA.~~  
24  
25  
26  
27 • Implementing NICE guidelines using a model OA consultation in primary care does  
28 not appear to lead to increased costs.  
29  
30  
31 • The model OA consultation appears to reduce referrals to orthopaedic surgery, and  
32 may result in less time off work.  
33  
34  
35  
36 • The model OA consultation is unlikely to be cost-effective  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Osteoarthritis (OA) is most prevalent in older people and is known to adversely affect quality of life [1-3]. Estimates from the USA suggest that 12.4 million adults over the age of 65 are living with this condition and around 2.9 million people have a disabling form of OA. A report by the Royal College of General Practitioners indicates that about 1 million adults consult with symptoms of OA in a year and it is one of the main reasons why people seek medical care [4-6]. The total healthcare cost of OA has been estimated at £1 billion in the UK [5]. Therefore OA places a considerable burden on scarce health care resources. The proportion of older people in the population has been increasing over time [7], and with this ageing population, it is expected that the prevalence of conditions such as OA will rise. A number of published guidelines have been developed to aid the treatment and management of OA [8-12]. In the UK for example, the National Institute for Health and Care Excellence (NICE) recommend that patients with OA should be offered core treatments when they first present in primary care. These include education and access to information, advice on local muscle strengthening exercise and general aerobic fitness, and if appropriate, advice on losing weight [12]. However, there is a gap between the care that is recommended and that which patients actually receive and that the core aspects of assessment and management of OA currently delivered in primary care do not meet the recommendations of these guidelines [13-14]. Therefore measures need to be put in place to ensure that resources are used optimally. Consequently, there was a need to develop a practical approach that could potentially support self-management of OA and also aid the implementation of the core NICE guidelines for OA. This led to the development of a model OA consultation [15] for older patients presenting with peripheral joint pain, and training for health care professionals to support its delivery. The model OA consultation integrated core recommendations from NICE and consisted of: an OA guidebook written by patients and health professionals for

1  
2  
3 patients, an enhanced initial consultation with a GP, and subsequent follow-up with a practice  
4  
5 nurse (up to 4 consultations) in a dedicated nurse-led OA clinic. In addition a practice e-  
6  
7 template was developed to record quality measures of care derived from a systematic review  
8  
9 of quality indicators for OA [15-16]. The Management of OsteoArthritis in Consultations  
10  
11 (MOSAICS) trial compared the model OA consultation with usual care over a 12 month  
12  
13 period. This paper reports the economic evaluation alongside the MOSAICS trial to assess  
14  
15 the cost-effectiveness of the model OA consultation compared with usual care in patients  
16  
17 who consult with OA.  
18  
19

## 20 21 **METHODS**

22  
23  
24 The economic evaluation was conducted alongside a two arm prospective pragmatic cluster  
25  
26 randomised controlled trial in eight general practices in Cheshire, Shropshire or Staffordshire,  
27  
28 UK. The protocol has been previously published [15]. The eight practices were randomised to  
29  
30 receive either the model OA consultation or usual care (control). Additional details of the  
31  
32 intervention can be found in appendix 1. The study was approved by the North West 1  
33  
34 Research Ethics Committee, Cheshire (REC reference: 10/H1017/76) and was monitored by  
35  
36 an Independent Trial Steering Committee and Data Monitoring Committee (Trial registration  
37  
38 number ISRCTN06984617). The primary outcome measure for the trial was the SF-12  
39  
40 physical component score [17].  
41  
42

43  
44 The health economic analysis initially took the form of a cost-consequence analysis where a  
45  
46 description of all the important results relating to costs and consequences (clinical outcomes,  
47  
48 EQ-5D, SF-6D, ICECAP-A) were reported. Subsequently, an incremental cost-utility  
49  
50 analysis using the quality adjusted life year as an outcome measure was undertaken from a  
51  
52 UK National Health Service (NHS) perspective.  
53  
54

## 55 **Data Collection**

56  
57  
58  
59  
60



### ***Resource Use and Costs***

Information on resource use and time off work due to joint problems were collected from the postal MOSAICS consultation questionnaires completed by participants at 6 months and 12 months follow-up. NHS costs included primary and secondary care contacts, investigations, medication and contacts with other health care professionals such as physiotherapists and occupational therapists. Questions on participant's personal expenditure focused on private health care use and over-the-counter treatments [15].

In order to value resource use, unit costs were obtained from standard sources such as the Unit Costs of Health and Social Care [18], the British National Formulary [19] and NHS Reference Costs [20] and applied to resource use data. Due to the lack of nationally representative unit cost estimates for private health care, this care was costed as the NHS equivalent. To obtain the cost of the model OA consultation, information on the resources used to deliver the intervention were obtained from patient records collected throughout the trial. To generate the intervention cost, we obtained records collected as part of the intervention. These records showed that the average number of times that trial participants actually saw their nurse from available records was 2.3 times. We therefore made the assumption that everyone in the intervention arm who actually saw the nurse did so at least 2.3 times. GP costs were not included as part of the intervention since all participants, irrespective of trial intervention arm received usual care. Costs associated with over the counter medication were based on participant responses to the postal questionnaires. Unit costs of the resource use items are presented in appendix 2 and are in 2012/2013 prices.

### ***Health and Quality of Life Outcomes***

All participants completed the 3-level version of the EuroQoL-5D (EQ-5D) questionnaire [21] at baseline, 3, 6 and 12 months. EQ-5D index scores were generated using the UK value

1  
2  
3 set [22] to calculate quality adjusted life years (QALYs) over the 12 month period which was  
4  
5 used in the base case analysis. (The QALY is an outcome measure that takes both the quality  
6  
7 and quantity of life associated with an intervention into account). Participants also completed  
8  
9 the SF-12 questionnaire [17] which was used to generate SF-6D scores [23] and the ICECAP-  
10  
11 A questionnaire at baseline, 3, 6 and 12 months. The ICECAP-A is a measure of capability  
12  
13 for adults, which aims to capture an individual's freedom to function in five key areas of their  
14  
15 life: attachment, autonomy, enjoyment, stability and achievement [24].  
16  
17

### 18 **Statistical Analysis**

19  
20  
21 Descriptive statistics were used to summarise the main health economic outcomes (EQ-5D  
22  
23 3L, SF-6D and ICECAP-A). The cost-utility analysis was focused on determining the  
24  
25 difference in costs and QALYs between the model OA consultation and usual care arms. To  
26  
27 ensure all eligible participants were included in the study, missing EQ-5D, SF-6D, ICECAP-  
28  
29 A and costs were imputed using multiple imputation methodology [25]. An imputation model  
30  
31 was fitted and included 25 imputed dataset. Using EQ-5D scores, QALYs over a 12 month  
32  
33 time period were calculated for each study participant with the area under the curve method  
34  
35 [26]. Imbalances in baseline utility (EQ-5D) scores between the model OA consultation and  
36  
37 usual care arms were controlled for using a multiple linear regression approach [27]. Mean  
38  
39 costs associated with each trial arm were estimated, and due to the skewed nature of the costs,  
40  
41 the difference in mean costs and 95% confidence intervals were calculated using non-  
42  
43 parametric bootstrapping [28]. Net monetary benefit ( $\Delta E * \lambda - \Delta C$ ) was also estimated for each  
44  
45 participant. This is defined as the change in effectiveness/QALYs ( $\Delta E$ ) multiplied by the  
46  
47 cost-effectiveness threshold ( $\lambda$ ) minus the change in cost ( $\Delta C$ ) [29]. The threshold value ( $\lambda$ )  
48  
49 used for the estimation of net benefits was £20,000 per QALY.  
50  
51  
52

53  
54 The base case took the form of a cost-utility analysis from a National Health Service (NHS)  
55  
56 perspective and was conducted using multilevel linear modelling (as participants are  
57  
58  
59  
60

1  
2  
3 clustered within GP practices), a method that has been recommended for the economic  
4 evaluation of cluster trials [30]. The dependent variables were net monetary benefits, costs,  
5 QALYs and cost of work absence. Independent variables included gender and baseline EQ-  
6 5D. Model estimates of the difference in costs, QALYs and net monetary benefits were used  
7 to derive an incremental cost per QALY gained and an incremental net monetary benefit.  
8  
9  
10  
11  
12

13  
14 Uncertainty was explored through the use of cost-effectiveness planes and cost-effectiveness  
15 acceptability curves (CEACs); these plot the probability that the intervention is cost-effective  
16 against willingness to pay threshold values [31]. All analyses were carried out in STATA 12,  
17 Realcom and Microsoft Excel [32-34]. Discounting was not required as the follow up period  
18 was 12 months.  
19  
20  
21  
22  
23

### 24 25 **Sensitivity Analysis**

26  
27 The sensitivity analysis had two main foci. The first was to explore uncertainties in the trial  
28 based data by using QALYs generated from the SF-6D to obtain cost-effectiveness estimates.  
29  
30 The second was to explore broader societal costs through the inclusion of private health care  
31 costs e.g. over the counter medication costs and private health care utilisation costs as well as  
32 productivity costs. The human capital approach [35], was used to estimate productivity costs  
33 using data collected on employment status at every time point and days off work due to their  
34 health. The average wage for each respondent was identified using UK Standard  
35 Occupational Classification coding and annual earnings data for each job type [36].  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 46 **RESULTS**

47  
48 A total of 525 participants across the 8 randomised practices were recruited to the cluster  
49 trial. Of these, 288 participants were in the practices randomised to the model OA  
50 consultation arm and 237 in practices randomised to the usual care arm. The mean age across  
51 all patients was 67.3 years (SD 10.4) and 59.5% were female. Follow-up rates at 6 and 12  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 months were 424 (81%) and 384 (73%) respectively in the intervention and control arms. A  
4  
5 total of 305 (58.1%) participants provided complete EQ-5D data at all time points.  
6  
7

### 8 **Resource use**

9  
10 Primary care visits were generally higher in the usual care arm. Although the differences  
11  
12 were not statistically significant, participants in the usual care arm had more visits to both the  
13  
14 GP and nurse. There was no significant difference in secondary care visits between trial arms  
15  
16 with the exception of visits to the orthopaedic surgeon which was significantly higher in the  
17  
18 usual care arm. Approximately 65% of participants in the usual care arm had prescribed  
19  
20 medication as compared to 59% in the model OA consultation arm (Table 1).  
21  
22  
23

### 24 **Health Outcomes**

25  
26 Mean EQ-5D and SF-6D scores increased at all time points over the 12 month period in both  
27  
28 the intervention and usual care arms indicating an improvement in health status over time.  
29  
30 Although these scores were higher in the usual care arm, the differences were not statistically  
31  
32 significant. When total QALYs were estimated, the usual care arm was associated with  
33  
34 marginally higher overall QALYs (in respect to both the EQ-5D and SF-6D). Also, the results  
35  
36 for the between-group differences in ICECAP-A showed similarly that the usual care arm  
37  
38 showed slightly higher average levels of capability across follow-up (Table 2). EQ-5D scores  
39  
40 were generally lower than SF-6D scores at all times.  
41  
42  
43  
44

### 45 **Costs**

46  
47 Overall NHS and health care costs were also higher in the usual care group compared with  
48  
49 the model OA consultation arm. However, these differences were not statistically significant  
50  
51 (Table 3). Table 3 also gives a breakdown of costs for each intervention. Use of primary and  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 secondary care, including visits to the orthopaedic surgeon, was greater in the usual care arm  
4  
5 leading to higher costs.  
6  
7

### 8 **Cost-effectiveness**

9  
10 Estimates from the regression model show that the intervention was associated with a lower  
11  
12 cost ( $p=0.705$ ) and fewer QALYs ( $p=0.786$ ) (Table 4). At a willingness to pay threshold of  
13  
14 £20,000 per QALY, the model OA consultation was associated with a 44% chance of being  
15  
16 cost-effective (Figure 1).  
17  
18

### 19 **Sensitivity Analysis**

20  
21  
22  
23 When broader health care costs were used, the intervention was still less costly ( $p=0.768$ ) and  
24  
25 less effective ( $p=0.786$ ) than the usual care arm (Table 5). Cost-utility analysis with QALYs  
26  
27 generated from the SF-6D yielded similar results to the base case analysis i.e. the intervention  
28  
29 was less costly ( $p=0.705$ ) and less effective ( $p=0.187$ ) than the usual care (Table 5). A total of  
30  
31 136 participants were in full time employment at baseline. Of these, 40 participants, 20 in  
32  
33 each trial arm took time-off over the 12 month period. Those in the intervention arm had  
34  
35 fewer mean days off work than those in the usual care arm ( $p=0.364$ ). The associated  
36  
37 productivity related cost was lower in the intervention arm but the difference was not  
38  
39 statistically significant (Table 5).  
40  
41  
42

## 43 **DISCUSSION**

### 44 **Summary of main findings**

45  
46  
47  
48  
49 This study sought to assess the cost-effectiveness of the model osteoarthritis consultation  
50  
51 (model OA consultation) for the implementation of NICE guidelines and support for self-  
52  
53 management of osteoarthritis in primary care. Our results reveal that there was a general  
54  
55 increase in health status across the whole population as measured by the EQ-5D and SF-6D  
56  
57  
58  
59  
60

1  
2  
3 over the 12 month period, and although scores were slightly higher in the usual care arm, the  
4 difference was not statistically significant. SF-6D scores were higher than EQ-5D scores, a  
5 result which was in line with a previous study [37]. With the exception of visits to the  
6 orthopaedic surgeon, which was higher in the usual care group, there were no significant  
7 differences in all other secondary care resource use items between the trial arms. Participants  
8 in the usual care arm also reported more time-off work compared to the intervention arm. The  
9 finding that the intervention may lead to reduced referrals and less time off work suggests a  
10 possible avenue for future research to identify individual patients who might benefit from the  
11 approach.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23 The model OA consultation was less expensive than usual care and although this was not  
24 statistically significant, one might argue that the exclusion of the cost of training resulted in  
25 this lower cost. However, it should be noted that there are difficulties associated with the  
26 estimation of a per patient training cost within economic evaluation studies and also training  
27 received would be used for a large number of patients over a number of years, resulting in a  
28 low mean cost per patient.  
29  
30  
31  
32  
33  
34  
35  
36

37 The cost-utility analysis showed that the model OA consultation was less costly but less  
38 effective than usual care. Even though these differences are not statistically significant, the  
39 established approach that is used in health economics is to conduct a cost-effectiveness  
40 analysis, focussing on the joint estimation of costs and outcomes [38]. At a cost-effectiveness  
41 threshold of £20,000 per QALY, the probability of the model OA consultation being cost-  
42 effective was low at 44%.  
43  
44  
45  
46  
47  
48  
49

### 50 **Strengths and weakness of the study**

51  
52  
53 A major strength of this study is that it is the first to consider the cost-effectiveness of the  
54 model OA consultation for the implementation of NICE guidelines and support for self-  
55  
56  
57  
58  
59  
60

1  
2  
3 management of OA in primary care. Second, the study considered cost-effectiveness in a  
4 population consulting with peripheral joint pain and OA in primary care. Much of the cost-  
5 effectiveness studies for OA are based on studies of knee OA and as such, our study  
6 considered a population where evidence of cost-effectiveness is lacking. Third, this study  
7 considered multiple outcomes and also considers outcomes broader than just health related  
8 quality of life which makes it unique from other health economic evaluations which consider  
9 a single outcome measure. This study is also associated with some limitations. First is the  
10 fact that the main outcome for the health economic analysis was the 3-level EQ-5D which  
11 may not be sensitive to changes in this disease area [39]. The five level version of the EQ-5D  
12 [40] is now available and this is likely to be more sensitive to change. Second, the difficulty  
13 associated with the estimation of a per patient training cost led to the exclusion of this cost  
14 from the analysis.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

### 29 **Meaning of the study**

30  
31  
32 Implementing NICE guidelines using a model OA consultation in primary care may not lead  
33 to increased costs. Although the intervention may support some people with OA to remain in  
34 work and reduce the demand for orthopaedic surgery, overall it is unlikely to be cost-  
35 effective.  
36  
37  
38  
39  
40  
41  
42  
43  
44

### 45 **Acknowledgements**

46  
47  
48 The project was undertaken with the support of Keele Clinical Trials Unit, Keele University,  
49 UK  
50  
51

### 52 **Conflict of interest statement**

53  
54  
55 The authors declare no conflicts of interest  
56  
57  
58  
59  
60

## Funding

This paper presents independent research funded by the Arthritis Research UK Centre in

Primary Care grant (Grant Number 18139).

**TABLE 1: Resource Use over 12 months Complete cases. All figures are means (standard deviations) except where indicated**

| Resource use category   | Model OA consultation (n=199) | Usual care (n=155) | Difference (Bootstrapped 95% Confidence Interval) |
|---|-------------------------------|--------------------|---|
| <b>Primary Care visits <sup>a</sup></b>                                   | 1.52 (2.46)                   | 1.99 (3.38)        | -0.48 (-1.18, 0.13)                               |
| <b>GP at practice</b>   | 1.32 (2.11)                   | 1.59 (2.62)        | -0.28 (-0.78, 0.24)                               |
| <b>GP at home</b>   | 0.02 (0.12)                   | 0.01 (0.08)        | 0.01 (-0.11, 0.03)                                |
| <b>Nurse at practice</b>  | 0.19 (0.67)                   | 0.39 (1.29)        | -0.20 (-0.48, -0.01)                              |
| <b>Nurse at home</b>  | 0                             | 0.01 (0.08)        | -0.01 (-0.03, 0)                                  |
| <b>Other healthcare professionals (attached to practice) <sup>d</sup></b> | 0.21 (0.86)                   | 0.32 (1.15)        | -0.12 (-0.33, 0.11)                               |
| <b>Secondary care visits <sup>b</sup></b>                                 | 1.11 (2.65)                   | 1.43 (2.91)        | -0.32 (-0.96, 0.27)                               |
| <b>Orthopaedic surgeon</b>  | 0.34 (0.89)                   | 0.58 (1.37)        | -0.24 (-0.52, -0.003)                             |
| <b>Podiatrist</b>   | 0.13 (0.92)                   | 0.12 (0.80)        | 0.003 (-0.17, 0.17)                               |
| <b>Physiotherapist</b>  | 0.61 (2.01)                   | 0.65 (1.93)        | -0.04 (-0.47, 0.36)                               |
| <b>Occupational therapist</b>   | 0.04 (0.21)                   | 0.07 (0.58)        | -0.04 (-0.16, 0.04)                               |
| <b>Other secondary care visits <sup>d</sup></b>                           | 0.16 (0.91)                   | 0.10 (0.51)        | 0.06 (-0.07, 0.24)                                |
| <b>Private consultants <sup>c</sup></b>                                   | 0.39 (1.66)                   | 0.57 (3.07)        | -0.18 (-0.79, 0.29)                               |
| <b>Private other health care professionals <sup>d</sup></b>               | 0.13 (0.85)                   | 0.04 (0.28)        | 0.09 (-0.02, 0.23)                                |
| <b>Hospital investigations/treatments <sub>d,e</sub></b>                  | 82 (41.21%)                   | 72 (46.45%)        | 10  |
| <b>Prescribed drugs <sup>d,e</sup></b>                                    | 117 (58.79%)                  | 101 (65.16%)       | 16  |
| <b>Over the counter drugs <sub>d,e</sub></b>                              | 98 (49.25%)                   | 72 (46.45%)        | 26  |

<sup>a</sup> Includes contacts with GP and Nurse at home and practice <sup>b</sup> Includes contacts with physiotherapists, occupational therapists podiatrists, and orthopaedic surgeons <sup>c</sup> Includes contacts with private physiotherapists, occupational therapists private podiatrists and private orthopaedic surgeons <sup>d</sup> Patient-specific <sup>e</sup> Figures are the



number of patients (percent) who stated that they had a investigation or a drug presented in this table were solely obtained from self report questionnaires \* Resource use items

**TABLE 2: Health Outcomes Mean (SD) over 12 months (imputed analysis)**

|                            | Model OA consultation (n=288) | Usual care (n=237) | Difference (Bootstrapped 95% Confidence Interval) |
|----------------------------|-------------------------------|--------------------|---|
| <b><i>EQ-5D scores</i></b> |                               |                    |   |
| Baseline                   | 0.573 (0.298)                 | 0.588 (0.272)      | -0.015 (-0.062, 0.039)                            |
| Month 3                    | 0.615 (0.280)                 | 0.631 (0.264)      | -0.016 (-0.064, 0.030)                            |
| Month 6                    | 0.637 (0.264)                 | 0.638 (0.259)      | -0.001 (-0.044, 0.044)                            |
| Month 12                   | 0.651 (0.262)                 | 0.674 (0.224)      | -0.023 (-0.067, 0.018)                            |
| QALYs                      | 0.627 (0.244)                 | 0.639 (0.224)      | -0.012 (-0.054, 0.026)                            |
| QALYs <sup>a</sup>         | 0.632                         | 0.634              | -0.002 (-0.25, 0.020)                             |
| QALYs <sup>b</sup>         |                               |                    | -0.003 (-0.026, 0.197)                            |
| <b><i>SF 6D scores</i></b> |                               |                    |   |
| Baseline                   | 0.678 (0.139)                 | 0.690 (0.148)      | -0.012 (-0.037, 0.013)                            |
| Month 3                    | 0.688 (0.141)                 | 0.696 (0.141)      | -0.008 (-0.033, 0.017)                            |
| Month 6                    | 0.687 (0.142)                 | 0.707 (0.144)      | -0.020 (-0.044, 0.004)                            |
| Month 12                   | 0.693 (0.139)                 | 0.702 (0.138)      | -0.009 (-0.032, 0.015)                            |
| QALY                       | 0.688 (0.128)                 | 0.701 (0.129)      | -0.013 (-0.038, 0.010)                            |
| QALY <sup>a</sup>          | 0.692                         | 0.696              | -0.004 (-0.03, 0.01)                              |
| QALYs <sup>b</sup>         |                               |                    | -0.012 (-0.03, 0.01)                              |
| <b><i>ICECAP A</i></b>     |                               |                    |   |
| Baseline                   | 0.826 (0.166)                 | 0.851 (0.155)      | -0.025 (-0.053, 0.003)                            |
| Month 3                    | 0.828 (0.151)                 | 0.853 (0.155)      | -0.025 (-0.053, 0.001)                            |
| Month 6                    | 0.821 (0.160)                 | 0.843 (0.158)      | -0.022 (-0.049, 0.005)                            |
| Month 12                   | 0.837 (0.153)                 | 0.846 (0.155)      | -0.009 (-0.038, 0.014)                            |

<sup>a</sup> adjusted for baseline Utility <sup>b</sup> difference in QALYs between trial arms adjusted for baseline Utility and gender (Regression model)

**TABLE 3: Mean per patient costs (SD) over 12 months (£)**

| Resource use category                  | Model OA consultation | Usual care     | Difference (Bootstrapped 95% Confidence Interval) |
|--|-----------------------|----------------|---|
|  | n=199 (£)             | n=155 (£)      |   |
| Primary Care visits <sup>a</sup>       | 56.01 (83.53)         | 69.02 (103.31) | -13.01 (-35.24, 5.28)                             |
| GP at practice                         | 44.76 (71.80)         | 54.18 (89.01)  | -9.42 (-29.03, 7.41)                              |
| GP at home                             | 0.81 (6.55)           | 0.35 (4.31)    | 0.46 (-0.71, 1.55)                                |
| Nurse at practice                      | 2.11 (7.46)           | 4.61 (15.07)   | -2.49 (-5.50, -0.03)                              |
| Nurse at home                          | 0                     | 0.15 (1.87)    | (-0.54, 0)  |
| Other primary care visits <sup>c</sup> | 8.33 (24.20)          | 9.74 (29.72)   | -1.41 (-7.37, 3.97)                               |
| Secondary care visits <sup>b</sup>     | 60.68                 | 76.48 (156.38) | -15.80 (-51.40, 14.01)                            |

|   |                                      |                           |  |
|---|--------------------------------------|---------------------------|--|
|   | (130.42)                             |                           |  |
| <b>Orthopaedic surgeon</b>                            | 27.09 (71.66)                        | 44.31 (106.94)            | -17.22 (-37.95, 1.18)                                    |
| <b>Podiatrist</b>                                     | 5.32 (35.65)                         | 4.34 (26.23)              | 0.98 (-5.03, 7.93)                                       |
| <b>Physiotherapist</b>                                | 21.55 (77.01)                        | 21.74 (70.72)             | -0.18 (-15.47, 16.50)                                    |
| <b>Occupational therapist</b>                         | 2.06 (11.98)                         | 2.24 (16.93)              | -0.18 (-3.50, 2.61)                                      |
| <b>Other secondary care visits<sup>c</sup></b>        | 4.67 (17.85)                         | 3.85 (22.67)              | 0.81 (-4.45, 4.65)                                       |
| <b>Hospital investigations/treatments<sup>c</sup></b> | 109.71 (401.16)                      | 92.36 (222.66)            | 17.35 (-42.40, 83.75)                                    |
| <b>Prescribed drugs<sup>c</sup></b>                   | 15.51 (20.34)                        | 15.65 (21.47)             | -0.14 (-4.58, 3.86)                                      |
| <b>Trial intervention cost</b>                        | 11.47 (20.69)                        | 0                         | 11.47 (8.69, 14.42)                                      |
| <b>Over the counter drugs<sup>c</sup></b>             | 27.14 (255.67)                       | 27.93 (121.01)            | -0.79 (-31.51, 50.14)                                    |
| <b>Private health professionals<sup>c</sup></b>       | 21.62 (76.54)                        | 29.53 (135.05)            | -7.91 (-39.24, 12.24)                                    |
| <b>Imputed analysis</b>                               |                                      |                           |  |
|   | <b>Model OA consultation (n=288)</b> | <b>Usual care (n=237)</b> | <b>Difference (Bootstrapped 95% Confidence Interval)</b> |
| <b>Total NHS costs<sup>d</sup></b>                    | 227.17 (411.84)                      | 236.11 (345.35)           | -8.94 (-71.79, 57.70)                                    |
| <b>Total Healthcare costs<sup>d</sup></b>             | 278.56 (535.43)                      | 285.99 (400.43)           | -7.43 (-76.41, 76.26)                                    |

<sup>a</sup> Includes contacts with GP and Nurse at home and practice <sup>b</sup> Includes contacts with physiotherapists, occupational therapists etc <sup>c</sup> Patient-specific <sup>d</sup> Unadjusted costs

**TABLE 4: Base case Cost-utility analysis (Imputed analysis)**

|  | <b>Difference in mean (Intervention-control)<sup>b</sup></b> | <b>P-value</b> | <b>Confidence Interval</b> | <b>Interpretation</b>                        |
|--|--|----------------|----------------------------|--|
| <b>NHS costs (£)<sup>a</sup></b>             | -13.11   | 0.705          | -81.09, 54.85              | Intervention less costly and less effective. |
| <b>QALYs<sup>a</sup></b>                     | -0.003   | 0.786          | -0.03, 0.02                |  |
| <b>Net monetary benefits (£)<sup>a</sup></b> | -33.63   | 0.887          | -497.56, 430.30            |  |

<sup>a</sup> adjusted for baseline Utility and gender <sup>b</sup> Difference in mean per patient cost and QALYs between trial arms

**TABLE 5: Sensitivity analysis**

|   | <b>Difference in mean (Intervention-control)<sup>b</sup></b> | <b>P-value</b> | <b>Confidence Interval</b> | <b>Interpretation</b> |
|---|--|----------------|----------------------------|-----------------------|
| <b>Cost-utility analysis with SF-6D</b> |  |                |                            |                       |
| <b>NHS costs (£)<sup>a</sup></b>        | -13.11   | 0.705          | -81.09, 54.85              | Intervention less     |

|  |         |       |                  |   |
|--|---------|-------|------------------|---|
| <b>QALYs (SF-6D)<sup>a</sup></b>                     | -0.012  | 0.187 | -0.03 , 0.01     | costly and less effective.                  |
| <b>Net monetary benefits (£)<sup>a</sup></b>         | -178.39 | 0.362 | -561.74 , 204.96 |   |
| <b>Cost-utility analysis with Health care costs</b>  |         |       |                  |   |
| <b>Health care costs (£)<sup>a</sup></b>             | -14.14  | 0.768 | -108.08, 79.80   | Intervention less costly and less effective |
| <b>QALYs<sup>a</sup></b>                             | -0.003  | 0.786 | -0.03 , 0.02     |   |
| <b>Net monetary benefits (£)<sup>a</sup></b>         | -34.95  | 0.883 | -501.82 , 431.92 |   |
| <b>Time off work and productivity costs</b>          |         |       |                  |   |
| <b>Number of days off over 12 months<sup>a</sup></b> | -1.05   | 0.364 | -3.35, 1.23      |   |
| <b>Mean cost (£) of work absence<sup>a</sup></b>     | -23.25  | 0.845 | -256.32, 209.83  |   |

<sup>a</sup> adjusted for baseline Utility, and gender (Regression model) <sup>b</sup> Difference in mean per patient costs net benefits, QALYs and time off work between trial arms

**REFERENCES**

- (1) Jinks C, Jordan K, Croft P. Disabling knee pain – another consequence of obesity: Results from a prospective cohort study. *BMC Public Health* 2006, **6**:258 doi:10.1186/1471-2458-6-258.
- (2) Cross M, Smith E, Hoy D et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. *Ann Rheum Dis* 2014;**73**:1323-30.
- (3) Murray CJ, Richards MA, Newton JN, et al. UK health performance: findings from the Global Burden of Disease Study *Lancet* 2013;**381**:997-1020.
- (4) Royal College of General Practitioners—Birmingham Research Unit, “Annual prevalence report,” Tech. Rep., 2006.
- (5) Chen A, Gupte C, Akhtar K, Smith P, Cobb J. (2012) The global cost of osteoarthritis: How the UK compares *Arthritis* 2012(2012) doi:10.1155/2012/698709
- (6) Jordan KP, Joud A, Bergknut C et al. (2013) International comparisons of the consultation prevalence of musculoskeletal conditions using population-based healthcare data from England and Sweden *Ann Rheum Dis* doi:10.1136/annrheumdis-2012-202634
- (7) Office for National Statistics (2014) Statistical Bulletin: Estimates of the very old (including centenarians) for the United Kingdom, 2002-2012  
[www.ons.gov.uk/ons/dcp171778\\_357100.pdf](http://www.ons.gov.uk/ons/dcp171778_357100.pdf)
- (8) Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of OA of the hip and knee: 2000 update. *Arthritis Rheum* 2000, **43**: 1905-1915.

- 1  
2  
3 (9) Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an  
4 evidence based approach to the management of knee OA: Report of a Task Force of  
5 the Standing Committee for International Clinical Studies Including Therapeutic  
6 Trials (ESCISIT). *Ann Rheum Dis* 2003, 62: 1145-1155.  
7  
8  
9  
10  
11 (10) Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the  
12 management of hip and knee OA, Part I: Critical appraisal of existing treatment  
13 guidelines and systematic review of current research evidence. *Osteoathr Cartil* 2007,  
14 15: 981-1000.  
15  
16  
17  
18  
19  
20 (11) Conaghan PG, Dickson J, Grant RL. Care and management of OA in adults:  
21 summary of NICE guidance. *BMJ* 2008, 336 :502-503.  
22  
23  
24 (12) NICE (2014) Osteoarthritis: care and management in adults  
25  
26 [www.nice.org.uk/Guidance/CG177](http://www.nice.org.uk/Guidance/CG177)  
27  
28  
29 (13) Porcheret M, Jordan K, Jinks C, with the Primary Care Rheumatology Society.  
30  
31 Primary care treatment of knee pain a survey in older adults. *Rheumatology* 2007, 46:  
32 1694-1700.  
33  
34  
35 (14) Steel N, Bachmann M, Maisey S, et al. Self reported receipt of care consistent with  
36 32 Quality Indicators: national population survey of adults aged 50 or more in  
37 England. *BMJ* 2008, 337: a957.  
38  
39  
40  
41 (15) Dziedzic K, Healey E, Porcheret M, et al. (2014) Implementing the NICE  
42 osteoarthritis guidelines a mixed methods study and cluster randomised trial of a  
43 model osteoarthritis consultation in primary care. *The Management of OsteoArthritis*  
44 In ConsultationS (MOSAICS) study protocol *Implement Sci* 9:5 doi:10.1186/s13012-  
45 014-0095-y  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (16) Edwards JJ, Khanna M, Jordan KP, et al (2013) Quality indicators for the primary  
4 care of osteoarthritis: a systematic Ann Rheum Dis 74: 490-498  
5  
6 doi:10.1136/annrheumdis-2013-203913  
7  
8  
9 (17) Ware JE, Kosinski M, Keller SD (1996) A 12-item Short-Form Health Survey.  
10 Construction of scales and preliminary tests of reliability and validity Med Care 34:  
11 220-33  
12  
13  
14  
15 (18) Curtis L (2012). Unit Costs of Health and Social Care 2012 PSSRU. University of  
16 Kent: Canterbury .  
17  
18  
19 (19) BMJ Group (2013). British National Formulary (BNF) 66. London: BMJ Group and  
20 RPS Publishing .  
21  
22  
23  
24 (20) Department of Health. NHS Reference Costs 2012/13.  
25  
26 (21) Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol  
27 Group Ann Med 33(5): 337-43  
28  
29  
30 (22) Dolan P (1997) Modeling valuations for EuroQol health states. *Med Care* , 1095-  
31 1108. JSTOR.  
32  
33  
34 (23) Brazier JE, Roberts J (2004) The estimation of a preference- based measure of  
35 health from the SF-12 Med Care 42: 851-859  
36  
37  
38 (24) Al-Janabi H, Flynn T, Coast J (2012) Development of a self-report measure of  
39 capability wellbeing for adults: The ICECAP-A Qual Life Res 21: 167-176  
40  
41  
42  
43 (25) Gomes M, Diaz-Ordaz K, Grieve R, Kenward RG (2013) Multiple imputation  
44 methods for handling missing data in cost-effectiveness analysis that use data from  
45 hierarchical studies: An application to cluster randomised trials Med Dec Making  
46 33(8): 1051-63  
47  
48  
49  
50 (26) Mathews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial  
51 measurements in medical research. BMJ 1990;300:230-5  
52  
53  
54  
55  
56  
57  
58  
59  
60


- 1  
2  
3 (27) Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial based cost  
4 effectiveness analysis: the importance of controlling for baseline utility. *Health Econ*  
5 14[5], 487-496. 2005. Wiley Online Library.  
6  
7  
8  
9 (28) Briggs AH, Gray AM (1999) Handling uncertainty when performing economic  
10 evaluation of health care interventions *Health Technol Assess* 3(2) PP 1-134  
11  
12 (29) Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'brien, B.J., Stoddart, G.L.  
13 2005. *Methods for the economic evaluation of health care programmes* Oxford  
14 University Press, USA.  
15  
16 (30) Gomes M, Ng ES, Grieve R, . (2012) Developing appropriate methods for cost-  
17 effectiveness analysis of cluster randomised trials *Med Dec Making* 32(2): 350-61  
18  
19 (31) Van Hout B, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E ratios  
20 alongside a clinical trial. *Health Econ* 1994; 3:309-19  
21  
22 (32) StataCorp. LP. *Stata/IC 12.1 for Windows*. 2012  
23  
24 (33) Carpenter JR, Goldstein H, Kenward G. REALCOM-IMPUTE software for  
25 multilevel multiple imputation with mixed responses types. *J Stat Soft*, 2011.  
26  
27 (34) Microsoft Excel for Windows, 2010, Redmont, VA, USA  
28  
29 (35) Sculpher M. (2001) The role and estimation of productivity costs in economic  
30 evaluation; in: Drummond MF, McGuire A (eds): *Economic evaluation in health care:*  
31 *merging theory with practice*. Oxford:: Oxford University Press, 94-112.  
32  
33 (36) Standard Occupational Classification (SOC) 2000  
34 [http://www.ons.gov.uk/ons/guide-method/classifications/archived-standard-](http://www.ons.gov.uk/ons/guide-method/classifications/archived-standard-classifications/standard-occupational-classification-2000/about-soc-2000/index.html)  
35 [classifications/standard-occupational-classification-2000/about-soc-2000/index.html](http://www.ons.gov.uk/ons/guide-method/classifications/archived-standard-classifications/standard-occupational-classification-2000/about-soc-2000/index.html)  
36  
37 (37) Whitehurst DG, Bryan S (2011) Another study showing that two preference based  
38 measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable.  
39  
40 But why should we expect them to be *Value Health* 14 PP 531-538  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 (38) Briggs AH, O'Brien BJ (2001) The death of cost-minimisation analysis? Health  
4  
5 Econ 10(2) PP 179-184  
6  
7 (39) Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML. (1999) Generic and  
8  
9 condition-specific outcome measures for people with osteoarthritis of the knee.  
10  
11 Rheumatology 38: 870-7  
12  
13 (40) Herdman M, Gudex C, Lloyd A et al. (2011) Development and preliminary testing  
14  
15 of the new five-level version of EQ-5D (EQ-5D-5L) Qual Life Res 20: 1727-36  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



297x209mm (300 x 300 DPI)

Review

## Appendix 1: The model OA consultation



### Model OA consultation with the GP

Patients with peripheral joint pain who were aged 45 years and over had an initial consultation with the GP where an OA e-template was triggered as part of the consultation and GPs were asked to assess and make a clinical diagnosis of the problem without the routine use of x-ray. GPs were then asked to offer an explanation of OA (in suitable language and tailored to the patient's level of understanding and individual circumstances) and offer first line analgesia as appropriate (paracetamol; Topical NSAIDs). An OA guidebook ([weblink:http://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA\\_Guidebook.pdf](http://www.keele.ac.uk/media/keeleuniversity/ri/primarycare/pdfs/OA_Guidebook.pdf)) written by patients and health care professionals for patients was given to the patient. It offers support for self-management, promotes the NICE core treatments and provides accounts of how people live with OA. The GP was then asked to explain the next steps: for the patient to read the OA guidebook and to arrange a follow-up appointment with the practice nurse.

### Model OA consultation with the Practice Nurse (nurse-led OA clinic)

The timing of the first appointment with the practice nurse was planned for a minimum of two weeks after the initial GP consultation. This gave patients time to read the guidebook and try those self-management strategies they felt were suitable. In the first consultation the practice nurse was asked to

1  
2  
3 refer to the guidebook as a resource to answer questions and clarify issues, ascertain the advice from  
4 the GP consultation, negotiate and agree appropriate goals, discuss the need for pain relief and  
5 opportunities for healthy eating, physical activity and exercise as appropriate.  
6  
7

8  
9 The timing of up to three follow-up visits with the nurse was agreed between the patient and the  
10 practice nurse, but was scheduled to be delivered within three months following the GP consultation.  
11

12 The follow-up practice nurse consultations were tailored to the patient's individual needs and could  
13 focus on, for example, reviewing the self-management plan, demonstrating exercises (Arthritis  
14 Research UK Exercises for Arthritis leaflet), giving advice as to how this could be maintained longer-  
15 term or making any necessary referrals to the broader multidisciplinary team. The practice nurse  
16 consultations were supported by a specifically tailored Case Report Form (available on request) and a  
17 nurse toolkit that included advice leaflets to give to patients (content of the toolkit available on  
18 request).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Appendix 2: Unit Costs (£) (2012/2013 prices)

| <b>Resource Use</b>                                   | <b>Unit costs</b> <sup>a</sup><br><b>Source</b> |
|---|---|
| <b>Primary Care visits</b> <sup>a</sup>               |   |
| GP visits per 11.7 minutes                            | 34  |
| Nurse visits at practice per hour                     | 44  |
| Nurse visits at home per hour                         | 60  |
| Other healthcare professionals (attached to practice) | Participant-specific                            |
| <b>Secondary care visits</b> <sup>b</sup>             |   |
| Orthopaedic surgeon                                   | 128   |
| Orthopaedic surgeon (follow-up)                       | 102   |
| Physiotherapist                                       | 49  |
| Physiotherapist (follow-up)                           | 44  |
| Occupational therapist                                | 75  |
| Occupational therapist (follow-up)                    | 34  |
| Podiatrist  | 74  |
| Podiatrist (follow-up)                                | 41  |
| Other secondary care visits                           | Participant-specific                            |
| Private consultants                                   | Costed to the NHS equivalent                    |
| Private other health care professionals               | Costed to the NHS equivalent                    |
| Hospital investigations/treatments                    | Participant-specific                            |
| Prescribed drugs <sup>c</sup>                         | Participant-specific                            |
| Over the counter drugs                                | Participant-specific                            |

<sup>a</sup> Curtis L Unit Cost of Health and Social Care 2013 PSSRU <sup>b</sup> NHS Reference costs schedule 2012/2013, <sup>c</sup> British National Formulary